Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
In DRAFT guidance, NICE does not recommend encorafenib plus cetuximab for the treatment BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment, as it is not considered cost-effective.
Source:
National Institute for Health and Care Excellence